EANS-Adhoc: SYGNIS Pharma AG / SYGNIS Pharma AG announces appointment of chairman of Management Board

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

C.E.O. Interviews

17.10.2012

Ad hoc-Release according to § 15 WpHG

SYGNIS Pharma AG announces appointment of chairman of Management
Board

Heidelberg, October 17, 2012 - SYGNIS Pharma AG (Frankfurt: LIOK;
ISIN DE000A1E9B74; Prime Standard) announces the appointment of Mrs.
Pilar de la Huerta to the Management Board of the Company and her
nomination as chairman of the Management Board (CEO) by the
Supervisory Board subsequently to today's Shareholders' Meeting.

**** end of ad hoc ****

For further information please contact:

SYGNIS Pharma AG

Peter Willinger
Co-CEO/CFO

Tel: +49 6221 454 836

Email: {willinger@sygnis.de}[HYPERLINK: mailto:willinger@sygnis.de]

### Disclaimer This publication is intended for information only and
constitutes neither an offer to sell nor an invitation to buy
securities. Some statements included in this press release, relating
neither to proven financial results nor other historical data, should
be viewed as forward-looking, i.e. not definite. Such statements are
mainly predictions of future results, trends, plans or goals. These
statements should not be considered to be total guarantees since
given their very nature they are subject to known and unknown risks
and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not
undertake to publicly update or revise these statements in the light
of new information or future results or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English